BioAtla, Inc. (BCAB)

BioAtla, Inc.'s stock price has declined significantly in the past six months, including a drop of 11.20% between January 2025 and January 2026, a 50% drop in the 10 days leading up to January 9, 2026, and a 74.87% decrease in the six months prior to August 2025. Key events impacting the stock include the Q3 2025 earnings call where the company reported a net loss of $15.8 million and decreased cash reserves, flexible financing agreements for up to $22.5 million, a $40 million SPV transaction with GATC Health to advance ozuriftamab vedotin, FDA alignment for a Phase 3 trial of ozuriftamab vedotin, and promising clinical data presentations.

BioAtla, Inc. does not experience demand seasonality for its products and services in the traditional sense, as its primary focus is on research, development, and clinical trials rather than commercial product sales. The demand for BioAtla's offerings is tied to the progress and success of its clinical programs, regulatory milestones, and potential partnerships.

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancer, utilizing its CAB and CIAO!™ platforms to create selective biologics that target the tumor microenvironment. The company's product candidates include Mecbotamab vedotin (BA3011) for sarcoma and NSCLC, Ozuriftabmab vedotin (BA3021) for melanoma, squamous cell carcinoma, NSCLC, and ovarian cancer, Evalstotug (BA3071) for melanoma, renal cell carcinoma, colorectal cancer, and NSCLC, BA3182 for advanced adenocarcinomas, BA3361 for tumors, BA3142 targeting B7-H3, and a preclinical candidate for CAB-Nectin 4 x CAB-CD3.

BioAtla, Inc. is headquartered in San Diego, California, USA, and has operations in Beijing, China, through a contractual relationship with BioDuro-Sundia.

BioAtla's brand reputation is characterized by promising scientific advancements and significant financial challenges. The company's CAB platform is viewed positively for its potential to develop safer and more effective cancer drugs, supported by extensive patent coverage. However, financial concerns, including a dwindling cash position and increased net losses, have raised questions about its long-term sustainability among investors.

BioAtla, Inc. has a mixed ownership structure with approximately 11.65% to 22.71% held by institutional investors, 6.87% to 9.32% by insiders, and around 71.01% by public companies and retail investors. Major institutional owners include Acorn Capital Advisors, Llc, Vanguard Group Inc, and Tang Capital Management Llc. Jay Short, co-founder and CEO, is also a significant individual owner.